Ventyx Biosciences (VTYX) 2025 Conference June 05, 2025 12:50 PM ET Speaker0 Don't worry, we would not miss this. Speaker1 Never a doubt, Mike. Speaker0 Good afternoon. I'm Michael Yee, a biotechnology analyst here at Jefferies. And very happy to moderate our next discussion with Ventix Biosciences. We have members of the of the team up here. We have Raju Mohan, CEO, and Matt Moore. Matt Moore. Fantastic. Maybe it would be a great opportunity, Raju, for you to just make some, broad opening comments. Ventix ...

Topline data from multiple Phase 2 studies expected throughout 2025 • Q2 readout from VTX3232 study in patients with early Parkinson’s disease • H2 readout from VTX2735 study in patients with recurrent pericarditis • H2 readout from VTX3232 study in participants with obesity and cardiometabolic risk factors Cash, cash equivalents and marketable securities balance of $228.8M as of March 31, 2025 expected to fund planned operations into at least H2 2026 SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Ventyx Bio ...